A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity. 2019

Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Immunotherapies have significantly improved cancer patient survival, but response rates are still limited. Thus, novel formulations are needed to expand the breadth of immunotherapies. Pathogen associated molecular patterns (PAMPs) can be used to stimulate an immune response, but several pathogen recognition receptors are located within the cell, making delivery challenging. We have employed the biodegradable polymer acetalated dextran (Ace-DEX) to formulate PAMP microparticles (MPs) in order to enhance intracellular delivery. While treatment with four different PAMP MPs resulted in tumor growth inhibition, cyclic GMP-AMP (cGAMP) MPs were most effective. cGAMP MPs showed anti-tumor efficacy at doses 100-1000 fold lower than published doses of soluble cGAMP in two murine tumor models. Treatment with cGAMP MPs resulted in increased natural killer cell numbers in the tumor environment. Immune cell depletion studies confirmed that NK cells were responsible for the anti-tumor efficacy in an aggressive mouse melanoma model. NK cells and CD8+ T cells were both required for early anti-tumor function in a triple negative breast cancer model. In summary, cGAMP MP treatment results in NK and T cell-dependent anti-tumor immune response.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008863 Microspheres Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers. Latex Beads,Latex Particles,Latex Spheres,Microbeads,Bead, Latex,Beads, Latex,Latex Bead,Latex Particle,Latex Sphere,Microbead,Microsphere,Particle, Latex,Particles, Latex,Sphere, Latex,Spheres, Latex
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009712 Nucleotides, Cyclic Cyclic Nucleotide,Cyclic Nucleotides,Nucleotide, Cyclic
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500

Related Publications

Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
December 2018, Cell reports,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
October 2019, Cell reports,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
January 2018, Journal of controlled release : official journal of the Controlled Release Society,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
February 2021, Oncotarget,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
January 2014, Journal of controlled release : official journal of the Controlled Release Society,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
June 2009, Frontiers in bioscience (Scholar edition),
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
May 2020, Immunological reviews,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
January 2012, Proceedings of the National Academy of Sciences of the United States of America,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
January 2022, Current stem cell research & therapy,
Rebekah Watkins-Schulz, and Pamela Tiet, and Matthew D Gallovic, and Robert D Junkins, and Cole Batty, and Eric M Bachelder, and Kristy M Ainslie, and Jenny P Y Ting
September 2022, Nature communications,
Copied contents to your clipboard!